MPO and atherosclerosis: The identification of vulnerable and stable plaque is a critical part of atherosclerosis treatment (Anderson and Morrow, 2017), with myeloperoxidase (MPO) being a potential inflammatory marker of vulnerable atherosclerotic plaque.